Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Fondazione IRCCS Istituto Nazionale Dei Tumori
Sponsor

Fondazione IRCCS Istituto Nazionale Dei Tumori

Italy Via Giacomo Venezian 1, 20133 Milan, Italy

About the sponsor

Research activity includes oncologic surgery with interest in reducing postoperative morbidity, managing inflammatory risk, and improving recovery after major cancer operations.

  • Postoperative morbidity
  • Inflammatory state
  • Perioperative risk reduction
  • Major oncologic surgery

Clinical work in this area also addresses patients undergoing complex surgical treatment for advanced abdominal and pelvic malignancies.

About Specializations

Fondazione IRCCS Istituto Nazionale Dei Tumori runs clinical trials in conditions such as Prophylaxis, Pseudomyxoma peritonei, Adenocarcinoma of colon, Gastroenteropancreatic neuroendocrine tumour disease, among others.

Recruiting now

Ongoing trials

Clinical trials run by this sponsor – those enrolling participants first.

Condition
Country
City
Type of trial
Recruitment status
Quick filters

25 clinical trials

Prophylaxis

Recruiting

Study on the Effects of Acetylsalicylic Acid and Cytisine for High-Risk Patients in Preventing Lung Cancer and Reducing Inflammation

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years · Healthy volunteers
  • Substances:Acetylsalicylic Acid
  • Sponsor:Fondazione IRCCS Istituto Nazionale Dei Tumori

Study of Pembrolizumab with Cisplatin or Carboplatin and Etoposide for Patients with Advanced Merkel Cell Carcinoma

Recruiting
Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:Fondazione IRCCS Istituto Nazionale Dei Tumori

Study on Preoperative Chemoradiotherapy with Capecitabine and Temozolomide for Patients with Locally Advanced Rectal Cancer

Recruiting
Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Capecitabine
  • Sponsor:Fondazione IRCCS Istituto Nazionale Dei Tumori

Pseudomyxoma peritonei

Recruiting

Study on Capecitabine and Cyclophosphamide for Patients with Large Pseudomyxoma Peritonei Preparing for Surgery and Chemotherapy

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Capecitabine
  • Sponsor:Fondazione IRCCS Istituto Nazionale Dei Tumori

Adenocarcinoma of colon

Recruiting

Study on Temozolomide and Irinotecan for Patients with Stage II/III Colorectal Cancer and Positive ctDNA After Chemotherapy

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Temozolomide
  • Sponsor:Fondazione IRCCS Istituto Nazionale Dei Tumori

Gastroenteropancreatic neuroendocrine tumour disease

Recruiting

Study on the Safety and Effectiveness of Cabozantinib and Lanreotide for Patients with Gastroenteropancreatic and Thoracic Neuroendocrine Tumors

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Cabozantinib
  • Sponsor:Fondazione IRCCS Istituto Nazionale Dei Tumori

Study on Pembrolizumab and Radiotherapy for Patients with High-Risk Soft Tissue Sarcoma in the Limbs

Recruiting
Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Pembrolizumab
  • Sponsor:Fondazione IRCCS Istituto Nazionale Dei Tumori

Bladder transitional cell carcinoma

Recruiting

Study of Cabozantinib and Durvalumab for Patients with Advanced Bladder Cancer After Chemotherapy

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Cabozantinib
  • Sponsor:Fondazione IRCCS Istituto Nazionale Dei Tumori

Hodgkin's disease+2

Recruiting

Study on Preventing Hypothyroidism in Patients with Medulloblastoma and Pediatric Lymphoma Using Levothyroxine During Radiation Therapy

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Levothyroxine
  • Sponsor:Fondazione IRCCS Istituto Nazionale Dei Tumori

Gastrointestinal carcinoma+1

Recruiting

Study on the Safety of Lanreotide and Metformin for Patients with Advanced Gastrointestinal or Lung Carcinoids

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Lanreotide
  • Sponsor:Fondazione IRCCS Istituto Nazionale Dei Tumori

Colorectal cancer

Recruiting

Study on Preventing Peritoneal Metastases in High-Risk Colorectal Cancer Patients Using Fluorouracil, Oxaliplatin, and Levoleucovorin After Surgery

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Fluorouracil
  • Sponsor:Fondazione IRCCS Istituto Nazionale Dei Tumori

Prophylaxis of nausea and vomiting

Recruiting

Study on Palonosetron and Netupitant for Preventing Nausea in Endometrial Cancer Patients Undergoing Taxane-Platinum Chemotherapy

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Atezolizumab
  • Sponsor:Fondazione IRCCS Istituto Nazionale Dei Tumori

Are you running a clinical trial?

Increase visibility for your trials and help patients find your site through our platform.

Join now →
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.